- Conditions: cUTI; Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified May 2012 - Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either 500 mg of Ciprofloxacin (oral); Drug: or 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified May 2012 - Condition: Alcoholic Liver Cirrhosis
Interventions: Other: Standard protocol of care; Biological: Allogeneic Mesenchymal Stem Cells; Biological: Allogeneic Mesenchymal Stem Cells; Biological: Allogeneic Mesenchymal Stem Cells
Sponsors: Stempeutics Research Pvt Ltd; Stempeutics Research Pvt Ltd
Not yet recruiting - verified April 2012 - Condition: Clostridium Difficile Associated Diarrhea
Interventions: Drug: Metronidazole; Drug: Metronidazole-DRF1; Drug: Metronidazole-DRF2
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited; Reliance Clinical Research Services (Navi Mumbai, India)
Recruiting - verified April 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 30; Drug: sitagliptin; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin; Drug: linagliptin; Drug: linagliptin medium dose; Drug: metformin placebo; Drug: metformin placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2012 - Condition: Osteoporosis, Postmenopausal
Interventions: Drug: denosumab; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Condition: Femur Neck Fracture
Interventions: Drug: Teriparatide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Schizophrenia
Interventions: Drug: Lurasidone; Drug: Matching Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium + olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus (HIV) Infection
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Epilepsy
Intervention: Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Atherosclerosis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: Iloperidone; Drug: Flexible dose Iloperidone including Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Post Herpetic Neuralgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Breast Neoplasms
Interventions: Drug: Afatinib 40mg once daily (OD); Drug: Vinorelbine 25 mg/m2 weekly; Drug: Paclitaxel 80 mg/m2 weekly
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Fibromyalgia
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Gastric Cancer
Intervention: Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: carboplatin; Drug: Paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo (Saxagliptin); Drug: Metformin IR; Drug: Placebo (Metformin); Drug: Metformin (Active Rescue)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: gemcitabine; Drug: carboplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: Aripiprazole; Drug: Aripiprazole
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2012 - Conditions: Neoplasms; Breast Neoplasms; Breast Cancer
Interventions: Drug: AZD8931; Drug: anastrozole; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Complicated Urinary Tract Infections or Pyelonephritis
Interventions: Drug: doripenem; Drug: doripenem placebo; Drug: cefepime; Drug: cefepime placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Conditions: Abscess, Intra-Abdominal; Abdominal Abscess; Abdomen, Acute; Abdominal Pain; Appendicitis; Rupture; Infection; Intestinal Perforation; Peritonitis; Ileus
Interventions: Drug: doripenem; Drug: meropenem placebo; Drug: meropenem; Drug: doripenem placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Metformin; Drug: Dapagliflozin Placebo; Drug: Pioglitazone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Fracture Healing
Interventions: Drug: Placebo; Drug: AMG 785 140 mg; Drug: AMG785 70mg; Drug: AMG 785 210mg
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673); Drug: Otamixaban matching placebo; Drug: Unfractionated Heparin; Drug: Unfractionated Heparin matching placebo; Drug: Eptifibatide; Drug: Eptifibatide matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Intra-Abdominal Infection
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Conditions: Blood Coagulation Disorders; Hemophilia A
Interventions: Biological: Recombinant Factor VIII (BAY81-8973); Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological: Recombinant Factor VIII (BAY81-8973); Biological: Recombinant Factor VIII (BAY81-8973)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Fracture Healing
Interventions: Drug: AMG 785 210mg; Drug: AMG 785 70mg; Drug: AMG 785 140 mg; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Pain, Perioperative
Interventions: Drug: Placebo; Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Congestive Heart Failure; Type II Diabetes Mellitus
Interventions: Drug: vildagliptin; Drug: placebo of vildagliptin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: NKTR-102; Drug: irinotecan
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012 - Condition: Renal Cell Carcinoma
Intervention: Other: Non Interventional
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia
Interventions: Drug: nilotinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010 - Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified August 2010 - Conditions: Epilepsy; Partial Seizure Disorder; Epilepsies, Partial; Complex Partial Seizure Disorder
Interventions: Drug: Pregabalin; Drug: Gabapentin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
 |
Join Clinical Trials that are held in Bangalore,India |
Clinical Trial Locations 